The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rapid cell expansion (RACE) technology for production of engineered autologous T-cell therapy: Path toward manageable multicenter clinical trials in aggressive NHL with anti-CD19 CAR.
Marc Better
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Omar Pugach
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Lily Lu
No relevant relationships to disclose
Robert Somerville
Research Funding - Kite Pharma
Sadik Kassim
No relevant relationships to disclose
James Kochenderfer
No relevant relationships to disclose
Steven A. Rosenberg
Research Funding - Kite Pharma
Margaret A. Marshall
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Adrian Bot
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Keith B. Nolop
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Margo Roberts
Employment or Leadership Position - Kite Pharma
Stock Ownership - Kite Pharma
Steven Feldman
Research Funding - Kite Pharma